

Amend
11. (Amended) The chimeric molecule of claim 10 wherein said RTD polypeptide comprises an extracellular domain sequence of claim 6 comprising amino acid residues 56 to 212 of Fig. 1A (SEQ ID NO:1).

A304
29. (Amended) A composition comprising the RTD polypeptide of claim 1 or claim 6 and a carrier.

sub D5
A4
34. (Amended) An article of manufacture, comprising a container and a composition contained within said container, wherein the composition includes the RTD polypeptide of claim 1 or claim 6 [or RTD antibodies].

sub D6
35. (Amended) The article of manufacture of claim 34 further comprising instructions for using the RTD polypeptide [or RTD antibodies] *in vivo* or *ex vivo*.

REMARKS

Claims 1-37 are pending in the application and are the subject of the office action issued by the Examiner.

In the office action, the Examiner set forth a restriction requirement pursuant to 35 U.S.C. Section 121, restricting the claims to six groups, Groups I - VI. Applicants hereby elect to prosecute claims drawn to Group I (directed to RTD polypeptides, chimeric molecules, and articles of manufacture) in the present application. Claims 15-28, 30-33, and 35-37 have been canceled in the above-amendment as being drawn to non-elected inventions.

Claims 6, 10, 11, 29, 34, and 35 were amended, as shown above, in an effort to clarify the various embodiments of the invention elected as a result of the present restriction requirement. It is believed that none of these amendments introduce new matter.

The undersigned does wish to bring to the Examiner's attention Applicants' co-pending application entitled "RTD Receptor" being examined by Examiner Ulm. In Applicants' co-pending application, Examiner Ulm also issued a restriction requirement. Parts of that restriction requirement are in conflict with the restriction requirement imposed in the present application. Specifically, Applicants' claims directed to